Merck Sharp & Dohme Llc

This study tests a new vaccine (V540A) designed to protect against more types of HPV, a virus that can cause cancer. It includes the 9 types covered by the current vaccine plus additional ones. About 525 healthy females aged 16 to 26 will receive either the new or current vaccine…

This early-stage study tests a new drug called MK-4884 in people with advanced or spreading solid tumors (like colorectal, kidney, lung, or bile duct cancer). The main goal is to check the drug's safety and find the right dose. About 120 participants will receive the drug, and re…

This study tests whether adding the targeted drug MK-1084 to the immunotherapy durvalumab helps people with a specific type of advanced lung cancer (KRAS G12C mutation) live longer without their cancer growing. About 310 adults who have finished chemotherapy and radiation without…

This early-stage study tests how a new HIV prevention drug (MK-8527) interacts with rifampin, a medicine for latent tuberculosis. Fourteen adults with latent TB will take both drugs, and researchers will measure drug levels in the blood. The goal is to see if the drugs can be use…

This early-stage study looks at how a single dose of the experimental drug MK-8527 changes the way the body processes methadone. Researchers will measure methadone levels in the blood of 14 healthy adults over 24 hours. The goal is to understand if MK-8527 affects methadone break…

This study looks at whether a single dose of ulonivirine changes how the body processes methadone. Fourteen healthy adults who are already on a stable methadone program will take methadone alone and then with ulonivirine. The goal is to measure drug levels in the blood to see if …